Study guide
9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax
Key Takeaways Explain This Topic AI
Light's criteria call fluid an exudate if the pleural/serum protein ratio exceeds 0.5, the pleural/serum LDH ratio exceeds 0.6, or the pleural LDH exceeds two-thirds of the upper limit of normal serum LDH; a diuresed heart failure effusion pseudo-exudates in 25-30% of cases and is confirmed transudative by a serum-to-pleural albumin gradient above 1.2 g/dL.
Heart failure effusions are usually bilateral and right-greater-than-left; post-CABG effusions are usually left-sided; hemothorax is defined by pleural fluid hematocrit at least 50% of serum, and chylothorax by pleural triglycerides above 110 mg/dL.
Tension pneumothorax is obstructive shock diagnosed clinically and decompressed with a 14-gauge, 5 cm or longer catheter at the fourth or fifth intercostal space anterior axillary line BEFORE any chest radiograph.
Absent lung sliding with absent B-lines and a barcode sign on M-mode suggests pneumothorax; the lung point is essentially 100% specific.
Thoracentesis is limited to 1,000-1,500 mL per session to prevent re-expansion pulmonary edema, and a suddenly silent mediastinal drain with rising CVP and narrowing pulse pressure after cardiac surgery means clotted tube with evolving tamponade until proven otherwise.
Last updated: August 2026
Why the Pleural Space Belongs on the CMC Blueprint
Test-plan item II.A.3 is not a thoracic-surgery lecture. Cardiac patients accumulate pleural fluid because their hearts fail, they develop pneumothoraces because we put catheters and leads into their chests, and they die of tension physiology and clotted mediastinal drains that a nurse could have caught. Every pleural problem in this section is either caused by cardiac disease, caused by cardiac procedures, or mistaken for cardiac decompensation.
Pleural Effusion: Transudate versus Exudate
The first fork in the road is whether the fluid crossed an intact membrane because of pressure (transudate) or leaked through an injured, inflamed membrane (exudate).
Light's Criteria
Fluid is an exudate if ANY ONE of the following is met:
- Criterion Exudate threshold
- Pleural fluid protein / serum protein Greater than 0.5
- Pleural fluid LDH / serum LDH Greater than 0.6
Pleural fluid LDH Greater than two-thirds of the upper limit of normal serum LDH (commonly above about 200 IU/L, laboratory dependent)
Light's criteria are about 98% sensitive for exudate but only about 80% specific, and the failure mode is precisely the patient you care for: a heart failure effusion that has been diuresed concentrates protein and LDH in the pleural fluid and gets misclassified as an exudate in roughly 25-30% of cases. When the clinical picture is clearly heart failure but Light's says exudate, the confirming tests are:
- Serum-to-pleural-fluid albumin gradient greater than 1.2 g/dL (transudate), or
- Serum-to-pleural-fluid protein gradient greater than 3.1 g/dL (transudate), or
Pleural fluid NT-proBNP above roughly 1,500 pg/mL , which supports a cardiac origin.
The Effusions You Will Actually See
Heart failure effusion. Bilateral in 55-70% of cases; when unilateral, right greater than left ; transudative, clear and straw-colored; resolves with decongestion. A unilateral left-sided effusion, an effusion with fever or pleuritic pain, or one that fails to respond to diuresis deserves a different explanation — do not attribute it to heart failure by default.
Post-cardiac-surgery effusion. Typically left-sided after CABG with internal mammary artery harvest and pleurotomy; usually small and self-limited. A late effusion appearing 2-4 weeks post-operatively with fever, pleuritic pain, elevated inflammatory markers and often a pericardial effusion suggests post-cardiac injury (Dressler) syndrome , which is exudative, often eosinophilic, and treated with NSAIDs plus colchicine rather than antibiotics.
Parapneumonic effusion and empyema. Uncomplicated parapneumonic effusions are free-flowing with pH above 7.20, glucose above 60 mg/dL and LDH under 1,000 IU/L, and respond to antibiotics alone. Complicated effusions (pH under 7.20, glucose under 60 mg/dL, LDH above 1,000, positive Gram stain, or loculation) require drainage. Empyema is frank pus or organisms on Gram stain and requires a chest tube, often with intrapleural alteplase 10 mg plus dornase alfa 5 mg twice daily for 3 days , or VATS decortication. This is a real complication of prolonged intubation and post-operative pneumonia in cardiac surgery patients.
Hemothorax. Pleural fluid hematocrit 50% or more of the serum hematocrit . Causes in the cardiac unit: subclavian or internal jugular line placement, pacemaker or ICD lead placement, pericardiocentesis, thoracentesis, chest compressions, anticoagulation with a small pleural injury, and rupture of a thoracic aortic aneurysm. Surgical exploration is indicated for an immediate drainage of 1,500 mL or more, or ongoing drainage above 200 mL/h for 2-4 hours.
Chylothorax. Milky, non-clearing drainage after thoracic duct injury — thoracic or cardiac surgery, high left internal jugular or subclavian cannulation, or central venous thrombosis. Confirmed by pleural fluid triglycerides above 110 mg/dL with chylomicrons present. Management: drainage, a low-fat diet with medium-chain triglycerides or total parenteral nutrition, octreotide, and lymphangiography with duct embolization or ligation if output persists. High-output chylothorax depletes protein, immunoglobulins and lymphocytes — nutrition and infection risk are nursing concerns.